In the latest trading session,, 6.45 million Viridian Therapeutics Inc (NASDAQ:VRDN) shares changed hands as the company’s beta touched 1.08. With the company’s most recent per share price at $15.84 changing hands around $1.65 or 11.63% at last look, the market valuation stands at $1.01B. VRDN’s current price is a discount, trading about -52.65% off its 52-week high of $24.18. The share price had its 52-week low at $10.93, which suggests the last value was 31.0% up since then. When we look at Viridian Therapeutics Inc’s average trading volume, we note the 10-day average is 1.09 million shares, with the 3-month average coming to 1.04 million.
Analysts gave the Viridian Therapeutics Inc (VRDN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.24. If we narrow down to specifics, the data shows that 0 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended VRDN as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight. Viridian Therapeutics Inc’s EPS for the current quarter is expected to be -1.05.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Viridian Therapeutics Inc (NASDAQ:VRDN) trade information
Instantly VRDN is in green as seen in intraday trades today. With action 9.47%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -27.27%, with the 5-day performance at 9.47% in the green. However, in the 30-day time frame, Viridian Therapeutics Inc (NASDAQ:VRDN) is 5.46% up. Looking at the short shares, we see there were 8.0 million shares sold at short interest cover period of 7.81 days.
The consensus price target for the stock as assigned by Wall Street analysts is 35, meaning bulls need an upside of 54.74% from its recent market value. According to analyst projections, VRDN’s forecast low is 20 with 51 as the target high. To hit the forecast high, the stock’s price needs a -221.97% plunge from its current level, while the stock would need to soar -26.26% for it to hit the projected low.
Viridian Therapeutics Inc (VRDN) estimates and forecasts
Data shows that the Viridian Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -19.55% over the past 6 months, a 25.24% in annual growth rate that is considerably higher than the industry average of 17.60%. Year-over-year growth is forecast to reach -10.80% down from the last financial year.
Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of 50k. 14 analysts are of the opinion that Viridian Therapeutics Inc’s revenue for the current quarter will be 50k. The company’s revenue for the corresponding quarters a year ago was 72k and 72k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -30.60%. The estimates for the next quarter sales put growth at -30.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.35%. The 2024 estimates are for Viridian Therapeutics Inc earnings to increase by 27.36%.
Viridian Therapeutics Inc (NASDAQ:VRDN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.01% of Viridian Therapeutics Inc shares while 111.05% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 111.06%. There are 111.05% institutions holding the Viridian Therapeutics Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 15.6686% of the shares, roughly 9.57 million VRDN shares worth $124.55 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.8129% or 4.77 million shares worth $62.1 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 1.77 shares estimated at $28.81 million under it, the former controlled 2.76% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.67% of the shares, roughly 1.71 shares worth around $27.83 million.
